Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Second Oncology Candidate (VTX-0P4) in a Prostate Stem Cell Antigen (PSCA) Related Tumor Study in Combination with a Checkpoint Inhibitor (CPI) / anti-mPD-1 [...]

Globally recognized manufacturing and product supply expert Tibor Nemes joins Scientific Advisory Board NEW YORK, NY, UNITED STATES, September 14, 2023/EINPresswire.com/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that Tibor Nemes, [...]

Self Assembling Vaccine targets Prostate Stem Cell Antigen Vaccine induces immunity against an immunogenic protein; expands platform’s potential targets NEW YORK, NEW YORK, UNITED STATES, September 6, 2023/EINPresswire.com/ -- Voltron Therapeutics, Inc., a Lucius [...]

Award will advance the Self-Assembling Vaccine Platform for rapid production of vaccines with Massachusetts General Hospital’s Vaccine and Immunotherapy Center NEW YORK, NY, UNITED STATES, August 17, 2023/EINPresswire.com/ -- Voltron Therapeutics, Inc., a Lucius Partners Portfolio [...]

Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoD Award will advance the Self-Assembling Vaccine Platform for rapid production of vaccines with Massachusetts General Hospital’s Vaccine and Immunotherapy [...]

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial Self Assembling Vaccine will target Prostate Stem Cell Antigen [...]